New data refine the choice between ropinirole and apomorphine

CURRENT FULL VERSION: A newly published 2025 study is sharpening the comparison between two familiar emetic options in dogs: ophthalmic ropinirole and apomorphine. The study, published March 17, 2025, in Frontiers in Veterinary Science, reported that the drugs achieved similar overall emesis success after up to two doses in 24 healthy dogs, but they did not perform the same way clinically. Apomorphine worked faster, while ropinirole led to more vomiting episodes, longer vomiting duration, and more frequent early antiemetic intervention. (frontiersin.org)

That finding lands in a practice environment where the regulatory and practical differences between the drugs already shape decision-making. Clevor, the ophthalmic ropinirole product distributed in the U.S. by Vetoquinol, was approved by the FDA under NADA 141-534 for induction of vomiting in dogs and is described by the company as the first and only FDA-approved product for emesis induction in dogs. Its label calls for administration by a veterinary professional, and the product is positioned as ready to use, without the compounding steps often associated with apomorphine. By contrast, apomorphine has no FDA approval in the U.S. for canine emesis, though it remains widely used extra-label in practice. (vetoquinolusa.com)

The new Frontiers paper compared IV apomorphine and ophthalmic ropinirole in a crossover design involving 24 healthy dogs. Overall success was high with both agents: 23 of 24 dogs vomited with apomorphine and 24 of 24 with ropinirole after up to two doses. But the timing differences were notable. Median time to first emesis was 1 minute 30 seconds with apomorphine versus 7 minutes 37 seconds with ropinirole. Median vomiting duration was 1 minute 13 seconds for apomorphine and 4 minutes 53 seconds for ropinirole. Dogs given ropinirole also had a median of four emetic episodes, compared with 2.5 for apomorphine, and 87.5% of ropinirole-treated dogs required early antiemetic treatment after more than three vomiting episodes, versus 29.2% of dogs given apomorphine. (frontiersin.org)

Those results partly align with, and partly complicate, the earlier evidence base. The pivotal ropinirole field study cited in Clevor’s prescribing information found that 94 of 99 treated dogs, or 95%, vomited within 30 minutes, supporting the product’s approval. Earlier published work also found ropinirole effective and easy to administer under veterinary supervision. But more recent emergency-setting data summarized in a 2025 PubMed record for Journal of Veterinary Emergency and Critical Care described ropinirole as having a lower first-dose success rate, slower onset, more minor adverse effects, and more protracted vomiting requiring rescue therapy than IV apomorphine. VetGirl’s discussion of that emergency-room study adds useful context: it was a prospective randomized clinical trial conducted from October 2021 to March 2023 at two specialty referral hospitals and included 132 client-owned dogs after suspected or confirmed toxin or foreign-body ingestion. Dogs were excluded if they were very young, very small, had ocular disease, had a history of CNS or hepatic disease, had ingested materials for which emesis was contraindicated, or had already received antiemetics. Cases included toxic foods such as chocolate, xylitol, and grapes or raisins; plants; medications; rodenticides and other poisons; and foreign material ranging from toys and cords to cloth items. Dogs were randomized to ropinirole eye drops or IV apomorphine, redosed if they had not vomited within 20 minutes, and monitored for 40 minutes, with outcomes including emesis success, time to first emetic event, number of emetic events, and need for rescue antiemetics. In other words, the broad message is becoming clearer: both drugs can be effective, but they are not interchangeable in every clinical sense. (vetoquinolusa.com)

Expert and professional commentary has been moving in that same direction. The University of Illinois College of Veterinary Medicine notes that both Clevor and apomorphine can be used when emesis is appropriate in dogs, while highlighting that Clevor is the FDA-approved ophthalmic option and apomorphine remains an extra-label drug with multiple administration routes. ASPCApro’s toxicology guidance likewise describes apomorphine as typically producing vomiting within about five minutes and notes that ropinirole is newer, with a more limited published literature base. Those perspectives don't dismiss ropinirole, but they frame it as a useful addition rather than a universal replacement. (vetmed.illinois.edu)

Why it matters: For veterinary teams, this is really a question of fit. A labeled, ready-to-use ophthalmic product may reduce friction in general practice, support standardization, and appeal to clinics that want to avoid compounded preparations or injections. At the same time, emergency and toxicology clinicians may weigh speed heavily, especially when the exposure window is narrow or the patient has ingested a foreign object or toxin where minutes matter. The newer comparative data suggest apomorphine may still offer an operational advantage in those scenarios, while ropinirole may be more likely to extend the vomiting event and require rescue antiemetic planning. Contraindications also remain central, particularly with ocular disease, seizure risk, central nervous system depression, or ingestion types where emesis is inappropriate. Rescue planning itself may also get easier as antiemetic options evolve: Dechra has announced FDA approval of Emeprev, a maropitant injectable described as the first FDA-approved bioequivalent to the most widely used antiemetic in companion animals. According to the company, the product contains benzyl alcohol, which may reduce injection pain in dogs, and it does not require refrigeration, potentially simplifying storage and access in busy clinics when antiemetic intervention is needed. (vetoquinolusa.com)

Another practical point is that emesis choice is only one part of decontamination strategy. Toxicology references emphasize that induced vomiting retrieves only part of gastric contents and should not be treated as a complete solution, particularly in poisoning cases. That means the selection between ropinirole and apomorphine sits inside a broader protocol that may include poison-control consultation, imaging, activated charcoal in selected cases, antiemetic follow-up, and monitoring for aspiration or prolonged signs. (vettimes.com)

What to watch: The next question is whether additional real-world studies in emergency patients, rather than healthy research dogs, will define clearer use cases for each drug. Watch for more data on first-dose success, adverse-event management, and whether clinics begin reserving ropinirole for situations where labeled status and ease of administration outweigh the slower onset and longer emesis profile seen in recent comparative reports. The specialty-hospital trial highlighted by VetGirl is especially relevant here because it reflects the kinds of mixed emergency presentations clinicians actually see, from toxic foods and medications to plants, rodenticides, and foreign-body ingestions. (frontiersin.org)